include ../../settings/boilerplate/global.pug
include ../general.pug
//- fragment 1
table(width="600" align="center" class="mobile-table" bgcolor="#FFFFFF")&attributes(tableAtt)
  tr
    td(align="left" class="frags" bgcolor="#ffffff")
      table(align="left" width="100%")&attributes(tableAtt)
        +vSpacer(1)
        tr
          td(align="left" class="fSize16 bText" style="font-weight: bold;")
            strong Acthar Gel has the potential for sustained effectiveness on disease activity in patients with persistently active RA
        +vSpacer(15)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                td(align="left" valign="top" width="5" class="bPoint") &bull;
                +hSpacer(12)
                td(align="left" class="fSize16") During the open-label period, Acthar Gel therapy was associated with significant improvements in: 
        +vSpacer(10)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") Disease activity scores (<span style="white-space:nowrap;word-break:keep-all;">DAS28-ESR</span> and CDAI) 
        +vSpacer(5)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16 mobile-hide" style="width:402px;max-width: 402px;") Swollen and tender joint counts
                <!--[if !mso]><!-->
                td(align="left" class="fSize16 mobile-show" style="display: none;") Swollen and tender joint counts
                <!-- <![endif]-->
        +vSpacer(5)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") Measures of fatigue (FACIT-F) and physical function (HAQ-DI)
        +vSpacer(5)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") The proportions of patients who met ACR20/50/70 criteria at Week 12
        +vSpacer(10)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                td(align="left" valign="top" width="5" class="bPoint") &bull;
                +hSpacer(12)
                td(align="left" class="fSize16") By Week 24 of the double-blind withdrawal period:
        +vSpacer(10)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") Significantly more patients treated with Acthar Gel than with placebo had maintained LDA, as assessed by <span style="white-space:nowrap;word-break:keep-all;">DAS28-ESR</span> and CDAI &le;10 
        +vSpacer(5)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") There was sustained effect of Acthar Gel on ACR20/50/70 for both Acthar Gel and placebo groups<sup class="sup">&dagger;</sup>
        +vSpacer(5)
        tr
          td
            table(align="left" width="100%")&attributes(tableAtt)
              tr
                +hSpacer(18,'m-td-w')
                td(align="left" valign="top" width="8" class="bPointHollow") &#9702;
                +hSpacer(12)
                td(align="left" class="fSize16") Cumulative disease activity flare rate was significantly lower for patients treated with Acthar Gel than those receiving placebo<sup class="sup">2</sup>
  tr
    td(align="left" class="bodyMain2Mobile" bgcolor="#ffffff")     
      table(align="left" width="100%")&attributes(tableAtt)
        tr
          td(align="left" width="5" class="fSize12" style="vertical-align:top;") <sup class="sup">&dagger;</sup>
          td(align="left" class="fSize12") ACR50 and ACR70 responses at Week 24 were evaluated post hoc.
  +vSpacer(20)
  tr
    td(align="left" class="bodyMainCTA" bgcolor="#ffffff")
      table(align="left" width="100%" bgcolor="#FFE5D9")&attributes(tableAtt)
        +vSpacer(15)
        tr
          td(class="mobile-hide ctaButton" style="padding-left:15px;padding-right:15px;")
            table&attributes(tableAtt)
              tbody
                tr
                  td(class="fSize16 bText" style="font-size: 16px;line-height: 21px;color: #333333;font-weight: bold;") Learn more about Acthar Gel RA clinical data
                  +hSpacer(60)
                  td(class="")
                    a(href='http://www.actharrheumatologyhcp.com/rheumatoid-arthritis/clinical-experience/two-part-multicenter-study/?utm_source=veeva&utm_medium=email&utm_campaign=ra_phase_iv_update&utm_content=Learn_more_ra_clinical_data', target='_blank')
                      img(src='./img/button-2.png', width='155', style='border:0; display:block;')
          <!--[if !mso]><!-->
          td(class="mobile-show ctaButton" width="100%" style="display: none;")
            table(align="center" width="100%")&attributes(tableAtt)
              tbody
                tr
                  td(class="fSize16 bText bodyMain2" align="center" style="text-align:center;font-size: 16px;line-height: 21px;color: #333333;font-weight: bold;padding-left:15px;padding-right:15px;") Learn more about Acthar Gel RA clinical data
                +vSpacer(10)
                tr
                  td(align="center")
                    a(href='http://www.actharrheumatologyhcp.com/rheumatoid-arthritis/clinical-experience/two-part-multicenter-study/?utm_source=veeva&utm_medium=email&utm_campaign=ra_phase_iv_update&utm_content=Learn_more_ra_clinical_data', target='_blank')
                      img(src='./img/button-2.png', width='155', style='border:0; display:inline-block;')
                +vSpacer(5)
          <!-- <![endif]-->
        +vSpacer(15)